TY - JOUR
T1 - The cancer-associated secretory phenotype
T2 - a new frontier in targeted therapeutics
AU - Tan, Xiaochao
AU - Xiao, Guan Yu
AU - Banerjee, Priyam
AU - Wang, Shike
AU - Kurie, Jonathan M.
N1 - Publisher Copyright:
Copyright: © 2024, Tan et al.
PY - 2024/9/3
Y1 - 2024/9/3
N2 - Oncogenic mutations activate secretory programs that drive tumor progression and represent therapeutic targets. The clinical relevance of CASPs is underscored by their prevalence, their linkages to specific genetic and epigenetic contexts, the proven efficacy of secretory blockade in preclinical models, and the availability of assays to identify vulnerable patient populations.
AB - Oncogenic mutations activate secretory programs that drive tumor progression and represent therapeutic targets. The clinical relevance of CASPs is underscored by their prevalence, their linkages to specific genetic and epigenetic contexts, the proven efficacy of secretory blockade in preclinical models, and the availability of assays to identify vulnerable patient populations.
UR - http://www.scopus.com/inward/record.url?scp=85203115569&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85203115569&partnerID=8YFLogxK
U2 - 10.1172/JCI182652
DO - 10.1172/JCI182652
M3 - Article
C2 - 39225096
AN - SCOPUS:85203115569
SN - 0021-9738
VL - 134
JO - Journal of Clinical Investigation
JF - Journal of Clinical Investigation
IS - 17
M1 - e182652
ER -
